GSK, Anaptysbio sue each other over Jemperli revenue

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Anaptysbio and its partner GSK are suing each other, claiming breach of contract over the big drugmaker’s license to market the likely blockbuster cancer immunotherapy Jemperli. A California-based developer of immune-modulating antibody drugs, Anaptysbio claimed in a Delaware court that GSK violated the terms of its decade-old deal by testing some of its experi ...